Literature DB >> 32190942

One-year outcomes for da Vinci single port robot for transoral robotic surgery.

Kathryn M Van Abel1, Linda X Yin1, Daniel L Price1, Jeffery R Janus1, Jan L Kasperbauer1, Eric J Moore1.   

Abstract

BACKGROUND: The da Vinci single-port (SP) robot is a new instrument for transoral robotic surgery (TORS) in oropharyngeal cancers (OPSCCs). We describe one-year SP surgical outcomes and compare them to da Vinci Si outcomes.
METHODS: Retrospective cohort study at a high-volume TORS center. Consecutive patients undergoing TORS SP procedures from 10/2018 to 09/2019 were included. SP OPSCC outcomes were compared to a historical cohort of Si OPSCC patients. t tests were used to compare continuous variables; χ2 or Wilcoxon rank-sum tests were used to compare nonparametric categorical variables.
RESULTS: Seventy-eight patients underwent SP TORS. The bleed rate was 5.1%, mortality rate was 2.6%, and conversion rate was 0%. Compared to the Si cohort, OPSCC patients undergoing TORS SP procedures saw no significant differences in operative time or post-TORS bleeds (P > .05).
CONCLUSIONS: The SP is a comparably safe surgical instrument. Overall learning curve for the SP was rapid among experienced TORS surgeons.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  HPV; TORS; oropharynx; single port; transoral robotic surgery

Mesh:

Year:  2020        PMID: 32190942     DOI: 10.1002/hed.26143

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

Review 1.  New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review of 2021.

Authors:  Alexander M Choi; Michael J Brenner; Daniel Gorelik; Isaac D Erbele; Matthew G Crowson; Prajoy Kadkade; Masayoshi Takashima; Peter L Santa Maria; Robert S Hong; Austin S Rose; Benjamin T Ostrander; Cyrus C Rabbani; Robert J Morrison; Philip A Weissbrod; Alan D Tate; Joshua J Kain; Ioan A Lina; Scott R Shaffer; Omar G Ahmed
Journal:  OTO Open       Date:  2022-09-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.